Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Glioblastoma 7Polycythemia Vera 6Gliosarcoma 6Leukemia 5Head and Neck Neoplasms 5Meningioma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Central Nervous System Neoplasms 3Thrombocythemia, Essential 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hypopharyngeal Neoplasms 2Glioma 2Congenital Abnormalities 2Carcinoma, Squamous Cell 2Astrocytoma 2

Interventions

Gemcitabine 27Fluorouracil 25Oxaliplatin 21Cisplatin 19Leucovorin 17Bevacizumab 15130-nm albumin-bound paclitaxel 13Docetaxel 12Capecitabine 12Albumin-Bound Paclitaxel 12Paclitaxel 11Irinotecan 10Carboplatin 9pembrolizumab 7Radiotherapy 6Pemetrexed 6Nivolumab 6Erlotinib Hydrochloride 6Cyclophosphamide 6Trastuzumab 5Ramucirumab 5Ipilimumab 4Everolimus 4Crizotinib 4Cetuximab 4vandetanib 3trastuzumab deruxtecan 3sargramostim 3folfirinox 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma × Hydroxyurea × Clear all
NCT00154375 2011-04-26

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Novartis

Phase 3 Completed
240 enrolled 8 charts
CNS

Adenocarcinoma, Astrocytoma, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡